ライフサイエンスコーパス: 5-fluorocytosine

1 replaced with the mechanism-based inhibitor 5-fluorocytosine.

2 ible to AmB and resistant to fluconazole and 5-fluorocytosine.

3 nucleotides identical in sequence containing 5-fluorocytosine.

4 me manner as cytosine, 5-methylcytosine, and 5-fluorocytosine.

5 and confer resistance to the antifungal drug 5-fluorocytosine.

6 um-dependent uptake of cytosine and can bind 5-fluorocytosine.

7 follows: amphotericin B, 1.0 micrograms/ml; 5-fluorocytosine, 0.25 micrograms/ml; fluconazole, 8.0 m

8 ar (PBM) cells, among which the cytosine 17, 5-fluorocytosine 18, and adenine 27 derivatives showed p

9 Cytosine 23, 5-fluorocytosine 25, and adenine 36 derivatives exhibite

10 ), guanine (18), 2,6-diaminopurine (20), and 5-fluorocytosine (30) derivatives were found to exhibit

11 (50) = 0.13 microM; EC(90) = 1.7 microM) and 5-fluorocytosine 35 (EC(50) = 0.031 microM; EC(90) = 0.3

12 we show that concurrent addition of prodrugs 5-fluorocytosine (5-FC) and ganciclovir (GCV) was less e

13 apy using bacterial cytosine deaminase (bCD)/5-fluorocytosine (5-FC) enzyme/prodrug strategy is limit

14 We used the cytosine deaminase (CD) 5-fluorocytosine (5-FC) enzyme/prodrug system and studie

15 (Ad) vector-mediated cytosine deaminase (CD)/5-fluorocytosine (5-FC) gene therapy has the potential t

16 y using the cytosine deaminase (CD) gene and 5-fluorocytosine (5-FC) has shown promising results for

17 the vv containing CD followed by the prodrug 5-fluorocytosine (5-FC) in a murine model of disseminate

18 V) encoding cytosine deaminase that converts 5-fluorocytosine (5-FC) into 5-fluorouracil in the tumor

19 sine deaminase, which converts the non-toxic 5-fluorocytosine (5-FC) into the toxic 5-fluorouracil (5

20 using bacterial cytosine deaminase (bCD) and 5-fluorocytosine (5-FC) is currently under investigation

21 The antifungal agent 5-fluorocytosine (5-FC) is used for the treatment of sev

22 observing the CD-catalyzed conversion of the 5-fluorocytosine (5-FC) prodrug to the chemotherapeutic

23 e, which efficiently metabolizes the prodrug 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU).

24 eaminase (CD) and is capable of metabolizing 5-fluorocytosine (5-FC) to 5-fluorouracil.

25 cytosine deaminase (CD) converts the prodrug 5-fluorocytosine (5-FC) to 5-FU.

26 no acid substitutions confers sensitivity to 5-fluorocytosine (5-FC) when expressed in the chloroplas

27 toconazole, amphotericin B, caspofungin, and 5-fluorocytosine (5-FC), respectively.

28 es the deamination of the nontoxic pro-drug, 5-fluorocytosine (5-FC), thus converting it to the cytot

29 ls followed by administration of the prodrug 5-fluorocytosine (5-FC).

30 imaging) to detect activation of the prodrug 5-fluorocytosine (5-FCyt) to the cytotoxic species 5-flu

31 ues with improved leaving ability, including 5-fluorocytosine, 5-bromocytosine, and 5-hydroxycytosine

32 terodimers of cytosine and 5-methylcytosine, 5-fluorocytosine, 5-bromocytosine, and 5-iodocytosine ar

33 (1, neplanocin A), cytosine (55, CPE-C), and 5-fluorocytosine (56) analogues exhibited moderate to po

34 Also, cytosine (55) and 5-fluorocytosine (56) analogues exhibited the most poten

35 h CD-expressing tumor cells are treated with 5 fluorocytosine (5FC), an inert prodrug that is convert

36 st effectively treated with a combination of 5-fluorocytosine (5FC) and amphotericin B.

37 ion of amphotericin B deoxycholate (AmB) and 5-fluorocytosine (5FC) by use of the Greco model of drug

38 uconazole, itraconazole, amphotericin B, and 5-fluorocytosine (5FC) by using National Committee for C

39 D) gene, which converts the nontoxic prodrug 5-fluorocytosine (5FC) into the chemotoxin 5-fluorouraci

40 5-fluorocytosine (5FC) is metabolized in CD-expressing c

41 CD also converts 5-fluorocytosine (5FC) to 5-fluorouracil, an inhibitor o

42 lso catalyzes the deamination of the prodrug 5-fluorocytosine (5FC) to form the anticancer drug 5-flu

43 fungal drugs rapamycin/FK506 (rap/FK506) and 5-fluorocytosine (5FC) were found when Cryptococcus was

44 ine, 5mZ), 5,6-dihydro-5-azacytosine (dhaC), 5-fluorocytosine (5FC), 5-chlorocytosine (5ClC), 5-bromo

45 f two substrates of the enzyme, cytosine and 5-fluorocytosine (5FC), can be detected using saturation

46 and C. zeylanoides) against amphotericin B, 5-fluorocytosine (5FC), fluconazole, and itraconazole.

47 ctor were much more sensitive to the prodrug 5-fluorocytosine (5FC), which is converted from the 5FC

48 vements in the ability to sensitize cells to 5-fluorocytosine (5FC).

49 cil, thymine, N4-benzoylcytosine, N4-benzoyl-5-fluorocytosine, 6-chloropurine, and 6-chloro-2-fluorop

50 itional expression of Fcy::Fur combined with 5-fluorocytosine administration improves tumor shrinkage

51 ynthesized racemic nucleosides, cytosine and 5-fluorocytosine analogues exhibited potent anti-HIV and

52 improved with intravenous amphotericin B and 5-fluorocytosine and did not require surgical interventi

53 nt Ad5-CD/TKrep virus followed by 2 weeks of 5-fluorocytosine and ganciclovir prodrug therapy can be

54 Two days later, patients were given 5-fluorocytosine and ganciclovir prodrug therapy for 1 (

55 t killing by the normally innocuous prodrugs 5-fluorocytosine and ganciclovir.

56 rvival of PC-3 cells in the presence of both 5-fluorocytosine and ganciclovir.

57 ene concomitant with increasing durations of 5-fluorocytosine and valganciclovir prodrug therapy and

58 Two days later, patients were administered 5-fluorocytosine and valganciclovir prodrug therapy for

59 sponse of HT-29 xenografts to treatment with 5-fluorocytosine and yCD adenovirus driven by either the

60 ity is strain-dependent, and fluconazole and 5-fluorocytosine are not active.

61 tosine deaminase is used in combination with 5-fluorocytosine as an enzyme-prodrug combination for ta

62 Oligonucleotides containing 5-bromo- or 5-fluorocytosine can bind to proteins that selectively b

63 adenoviral (Ad5)-directed cytosine deaminase/5-fluorocytosine (CD/5-FC) enzyme/prodrug gene therapy t

64 Cytosine deaminase/5-fluorocytosine (CD/5-FC) is a promising strategy for l

65 a target oligodeoxyribonucleotide containing 5-fluorocytosine confirmed the existence of this dihydro

66 as active and formed a covalent complex with 5-fluorocytosine-containing RNA, whereas the mutant at t

67 Moreover, the efficiency of 5-fluorocytosine conversion into 5-fluorouracil in tumor

68 ir/herpes simplex virus thymidine kinase and 5-fluorocytosine/cytosine deaminase.

69 When 5-fluorocytosine (F) is placed at the targeted cytosine

70 The MICs of amphotericin B, 5-fluorocytosine, fluconazole, and itraconazole were det

71 UPRT that could catalyze the modification of 5-fluorocytosine into chemotherapeutic 5-fluorouracil (5

72 in converting systemically injected nontoxic 5-fluorocytosine into the toxic anticancer drug 5-fluoro

73 genetically modified cells are combined with 5-fluorocytosine, it creates a potent negative selection

74 They are rejected by normal mice without 5-fluorocytosine prodrug treatment.

75 nce of the systemically administered prodrug 5-fluorocytosine produced statistically significant redu

76 form abortive covalent complexes at targeted 5-fluorocytosine residues in DNA.

77 hecin glucuronide to 9-aminocamptothecin and 5-fluorocytosine to 5-fluorouracil (5-FU) and further to

78 ast cytosine deaminase (yCD), which converts 5-fluorocytosine to 5-fluorouracil, to increase targetin

79 same enzyme also catalyzes the conversion of 5-fluorocytosine to 5-fluorouracil; this activity allows

80 e, catalyzes the deamination of cytosine and 5-fluorocytosine to form uracil and 5-fluorouracil, resp

81 Resistance to the antifungal drug 5-fluorocytosine was not deleterious and appeared to be

82 be, MICs of amphotericin B, fluconazole, and 5-fluorocytosine were determined.

83 own CodB as also important for the uptake of 5-fluorocytosine, which has been suggested as a novel dr

84 -fluorouracil (5-FU) from the benign prodrug 5-fluorocytosine within colorectal cancers.

85 nciclovir (TK/GCV), yeast cytosine deaminase/5-fluorocytosine (yCD/5-FC) and nitroreductase/CB1954 (N